TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01001949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Bran Extract
Description: soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
Study: NCT00876460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 M + docetaxel M
Description: BIBF 1120 Medium dose bid + docetaxel 60 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 M + docetaxel H
Description: BIBF 1120 Medium dose bid + docetaxel 75mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 H + docetaxel H
Description: BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 L + docetaxel M
Description: BIBF 1120 Low dose bid + docetaxel 60 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 H + docetaxel M
Description: BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
Study: NCT02765022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clip closure
Description: Complete clip closure of secondary lesions after the endoscopic mucosal resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No clip closure
Description: Observation: no clip closure of secondary lesions after the endoscopic mucosal resection
Study: NCT04580693

Intervention type: OTHER
Intervention: PET Scan
Description: PET scan using a tracer that is under a physician sponsored IND.
Study: NCT03115554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI Plus Catheter Ablation
Description: Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI Alone
Description: Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
Study: NCT04255342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant Placement and Temporary Crown using AstraTech Implant System EV, Final Crown Delivery
Description: At least 3 months after tooth removal and bone grafting, a dental implant will be placed using Azento, a commercially-available product that uses computer technology to plan the dental implant placement using the AstraTech Implant System EV and an immediate implant temporary crown using Azento. After 3 months with the temporary crown, a definitive all-ceramic crown, made using a digital workflow will be placed.
Study: NCT04580693

Intervention type: OTHER
Intervention: PET Scan
Description: PET scan using a tracer that is under a physician sponsored IND.

Intervention type: OTHER
Intervention: PET Scan
Description: PET scan using a tracer that is under a physician sponsored IND.
Study: NCT02592317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 56021927
Description: JNJ 56021927 will be administered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail
Description: Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
Study: NCT02691013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05154500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron biofortified potato
Description: A non-blinded randomized cross-over design with multiple meal feedings will be used to quantify iron bioavailability from iron biofortified and non-biofortified potatoes. Women volunteers will consume biofortified ('A') and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p\<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p\>0.05). Based on this study design, every woman is her own control.
Study: NCT02961114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose
Description: Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IV Sterile Normal Saline
Description: Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
Study: NCT01147692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: simvastatin plus albiglutide
Description: A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
Study: NCT02705859

Intervention type: DRUG
Group type: OTHER
Intervention: Copanlisib
Description: Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Description: Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
Study: NCT05154500

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Iron biofortified potato
Description: A non-blinded randomized cross-over design with multiple meal feedings will be used to quantify iron bioavailability from iron biofortified and non-biofortified potatoes. Women volunteers will consume biofortified ('A') and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p\<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p\>0.05). Based on this study design, every woman is her own control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc biofortified potato
Description: A crossover study will be used to compare zinc bioavailability of biofortified and non-fortified potatoes. Nutritional pre-screening is not required as there are no major systemic influences on zinc absorption.Volunteers will be randomly assigned to consume first either the biofortified or the non-biofortified potato, and consume the second potato-type 30 days later. Zinc absorption from two meals of biofortified or non-fortified potato will be measured using the double stable isotope technique.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Zinc biofortified potato
Description: A crossover study will be used to compare zinc bioavailability of biofortified and non-fortified potatoes. Nutritional pre-screening is not required as there are no major systemic influences on zinc absorption.Volunteers will be randomly assigned to consume first either the biofortified or the non-biofortified potato, and consume the second potato-type 30 days later. Zinc absorption from two meals of biofortified or non-fortified potato will be measured using the double stable isotope technique.
Study: NCT02409563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (100 mcg bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (50 mcg bid
Study: NCT03549442

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BCMA CART + huCART19
Description: The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CART BCMA or CART BCMA + huCART19
Description: The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive CART-BCMA + huCART19. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Single-dose infusion of CART BCMA or CART BCMA + huCART19
Description: The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA + huCART19. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BCMA CART + huCART19
Description: The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
Study: NCT04057547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified Gegen Qinlian Decoction
Description: Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Gegen Qinlian Decoction
Description: Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
Study: NCT03057054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo alloHCT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo alloHCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum strain 299
Description: Given PO or via NJ, NG or G tube

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum strain 299v
Description: Given PO or via NJ, NG or G tube

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO or via NJ, NG or G tube
Study: NCT03721055

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-(2S,4R)4-fluoroglutamine
Description: Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
Study: NCT02278120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib (600 mg, in three 200 mg hard gelatin capsules) was administered orally once daily on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen (20 mg, tablets) was administered orally on a continuous daily schedule (days 1-28 of each 28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen (20 mg, tablets) was administered orally on a continuous daily schedule (days 1-28 of each 28-day cycle)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole (1 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole (1 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Goserelin
Description: Goserelin (3.6 mg, subcutaneous implant) was administered on day 1 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin (3.6 mg, subcutaneous implant) was administered on day 1 of every 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (hard gelatin capsules) was administered orally once daily on Days 1-21 of each 28-day cycle.
Study: NCT02401516

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Reprogramming insoles
Description: 1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reprogramming insoles
Description: 1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
Study: NCT04582929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuronox ® Injection
Description: Neuronox ® 50 or 100 unit intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuronox ® Injection
Description: Neuronox ® 50 or 100 unit intramuscular injection
Study: NCT03530605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune TTF device
Description: portable device which produces electrical fields
Study: NCT06766786

Intervention type: DRUG
Intervention: Magnesium Sulfate high dose
Description: Patients undergoing simultaneous pancreas-kidney (SPK) transplantation who gave their consent were given an intravenous magnesium supplement at a dose of 45-50 mg/kg over the course of an hour during the procedure.
Study: NCT03204929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu(II)ATSM
Description: copper-containing synthetic small molecule
Study: NCT01671995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nurse monitored heart failure program
Description: Standard program for a heart failure clinic with information, education, drug titration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard primary health care
Description: Standard care in primary care according to national guidelines but at the discretion of the primary care caregiver
Study: NCT01850147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib, chemotherapy
Description: sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
Study: NCT01197625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine
Description: Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin
Study: NCT02966678

Intervention type: PROCEDURE
Intervention: Color Vision Test
Description: Farnsworth Panel D15/Hue test plus Ishihara charts
Study: NCT04245540

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pau d' Arco
Description: Encapsulated herbal Pau d' Arco.
Study: NCT05320783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: Classical music pre-selected was started to the patients with individual comfortable volume.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: music player was not started.
Study: NCT04293913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: illustrated communication material
Description: Illustrated communication material was introduced to the patients in the intervention group. In the process (intensive care) that patients received mechanical ventilation support after the operation, agitation and sedation levels were monitored by the intensive care nurse who was to communicate with the patient using the Richmond Agitation Sedation Scale (RASS). According to this scale, having minimum -2 and maximum +2 points was accepted as the starting criteria for communication (Sessler et al., 2002). Communication was established with the illustrated communication material.
Study: NCT02891434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acquisition on TouchScreen
Description: Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquisition on TouchScreen
Description: Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acquisition on Kinect
Description: Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquisition on Kinect
Description: Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acquisition on LeapMotion
Description: Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquisition on LeapMotion
Description: Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
Study: NCT02079467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unrestricted rehabilitation
Description: Standard care range of motion restrictions will not be used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Standard care range of motion restrictions will remain in place
Study: NCT02402257

Intervention type: BEHAVIORAL
Intervention: CVC Train the Trainer
Description: Trainees receive a simulation-based mastery learning intervention and train-the-trainer program on central venous catheter insertion
Study: NCT02219581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg
Description: Two doses of dexamethasone 10 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg
Description: Two doses of dexamethasone 20 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard multimodal pain management regimen
Description: The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~* Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~* Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~* Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. The dose is 15 mg for older patients or if creatinine clearance (CrCl) is low.~Postoperative~* Tylenol: 1000mg po q 8hr (scheduled)~* Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~* IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~* Morphine patient-controlled analgesia (PCA): only for failure of the above~* Morphine Sulfate (MS) Contin: Use as backup prn pain